Selexis SA

Unsere wichtigsten Marktleistungen

• MARtech
  Selexis has developed a superior technology that boosts eukaryotic recombinant protein production processes. The technology is based on the observation that genetic elements involved in the dynamic of chromatin called Matrix Attachment Regions (MARs) are pivotal for heritable transmission of gene expression patterns. MARs have been shown to be associated with remodeling of the surrounding chromatin, thus promoting transgene expression in the form of an active artificial transcriptional domain. MAR elements are highly active when a transgene cassette co-integrated within the chromosome of the eukaryotic host cell (stable expression mode). MAR elements have also been shown to be active when a transgene cassette is not integrated (transient expression mode). These features make MARtech extremely valuable in different areas of the biotechnology industry that relies on the production of human recombinant protein targets for drug discovery or on the production of therapeutic proteins (e.g. antibodies). To date, Selexis has signed several contracts with major Pharmaceutical and Biotechnology companies in order to enhance the production of recombinant protein drugs.
• Drug dicovery platform
  Selexis has developed an original drug discovery platform that combines its proprietary technology MARtech for the rapid production of human recombinant protein targets with a powerful selection tool to rapidly identify hit compounds against the protein targets. These hits are further evolved towards leads by using recombinant DNA techniques. The potential lead compounds are then assayed in vivo in pre-clinical tests using cell culture and mice bearing human tumor xenografts.